Literature DB >> 12610447

[Bilateral pneumothorax and tamponade after acupuncture].

R Cantan1, N Milesi-Defrance, K Hardenberg, M Vernet, I Messant, M Freysz.   

Abstract

INTRODUCTION: The "target" of acupuncture is usually the muscle, but it occasionally approaches other anatomical structures such as the pleura, which may subsequently suffer damage. OBSERVATION: During a session of acupuncture, a 25-year-old woman had a malaise with shock and neurological disorders. The initial examinations revealed a bilateral pneumothorax associated with pericardial and peritoneal effusions. Symptomatic reanimation combining dopamine, left pleural draining and pericardial puncture led to rapid haemodynamic improvement. The etiological exploration, having eliminated an underlying pathology, concluded in the diagnosis of tamponade and bilateral pneumothorax following a session of acupuncture. COMMENTS: Our patient presented the association of two traumatic complications of acupuncture: cardiac tamponade due to haemopericardium and bilateral pneumothorax. Although these complications are rare, they must be known.

Entities:  

Mesh:

Year:  2003        PMID: 12610447

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  4 in total

1.  Acupuncture-Related Pneumothorax.

Authors:  David A Hampton; Robert T Kaneko; Erika Simeon; Alexis Moren; Susan Rowell; Jennifer M Watters
Journal:  Med Acupunct       Date:  2014-08-01

2.  Acupuncture therapy related cardiac injury.

Authors:  Xue-feng Li; Xian Wang
Journal:  Chin J Integr Med       Date:  2013-06-05       Impact factor: 1.978

3.  Hemopericardium following acupuncture.

Authors:  Jung Heon Kim; Sun Hyu Kim; Yong Jik Lee; Jung Seok Hong; Ryeok Ahn; Eun Seog Hong
Journal:  Yonsei Med J       Date:  2011-01       Impact factor: 2.759

4.  An exploration of the needling depth in acupuncture: the safe needling depth and the needling depth of clinical efficacy.

Authors:  Jaung-Geng Lin; Pei-Chi Chou; Heng-Yi Chu
Journal:  Evid Based Complement Alternat Med       Date:  2013-07-09       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.